Opioid use in pregnancy and Neonatal Abstinence Syndrome

Similar documents
Ohio Perinatal Quality Collaborative

NOWS The Time Caring for the Infant with Neonatal Opiate Withdrawal Syndrome

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC

Objectives. Care of the Neonate with Prenatal Opioid Exposure. What is Neonatal Abstinence Syndrome (NAS)? Increasing Incidence of NAS 8/27/2016

Opioid Use Disorder in Pregnancy. Neonatal Abstinence Syndrome

Neonatal Narcotic Abstinence Syndrome: A National Epidemic

Maternal and Child Health, Substance Abuse Ohio Department of Health, Bureau of Maternal Child and Family Health

NEONATAL ABSTINENCE SYNDROME (NAS) AKA NEWBORN DRUG WITHDRAWAL:THE NEWARK EXPERIENCE

Lori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center

Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015

Welcome to the OPQC NAS November Action Period Call

MOMS Project Panel Overview

Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)

Neonatal Abstinence Syndrome:

Opioids in Pregnancy. Beyond to Baby GENERAL INFO

Neonatal Abstinence: The epidemic Its Impact on All of Us

Supersedes Date None and Management Guidelines. Originating Dept. NICU Document Owner Dir., NICU Document applies to: NCH Required Not Required

9/19/13. Postpartum Counseling for Women in MAT. Katie Clark MSPH, CSAC. A little about Katie. Definitions. MAT: Medication-Assisted Treatment

Care of the Neonate with Prenatal Opioid Exposure. Objectives. What is Neonatal Abstinence Syndrome (NAS)/ Neonatal Opiate Withdrawal Syndrome?

Clinical Management of Neonatal Abstinence Syndrome. Tricia L. Romesberg, DNP, MSN, ARNP, CNNP

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

Neonatal abstinence syndrome

Methadone and Pregnancy

The Opioid-Exposed Woman

Neonatal Abstinence Syndrome (NAS)

Neonatal Abstinence Syndrome:

Neonatal Drug Withdrawal

HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder

Neonatal Abstinence Syndrome Epidemiology, diagnosis, management and prevention

The Impact of Addiction on Infant Mortality

PROJECT DOVE. Improving Maternal and Neonatal Health Through Safer Opioid Prescribing

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

SERVING SUBSTANCE EXPOSED NEWBORNS IN HARFORD COUNTY

Opioid Use Disorders and Pregnancy. Marcela Smid, MD Maternal-Fetal Medicine

Substance-Exposed Newborns

Mental and Behavioral Health

Beyond Birth: A Comprehensive Recovery Center serving parenting women

Neonatal Abstinence Syndrome

The Opioid Crisis. National and State Initiatives

Just Out of Reach: Women Who Use Drugs, Stigma and Barriers to Care Erin Bortel and Lyla Hunt AIDS Institute Office of Drug User Health

Opioid Task Force Kick-Off Meeting. February 29, 2016

Effects of Prenatal Illicit Drug. Use on Infant and Child

4/19/2018. Opioid Use Disorder in Pregnancy OBJECTIVES ANTENATAL TESTING

Brief History of Methadone Maintenance Treatment

Opioid Abuse Treatment in Pregnancy

Illicit Opioid and Methamphetamine Trends in Maine

Opioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard

Neonatal Abstinence Syndrome: Focus on Prevention and Role of Collaboratives

Clinical Policy: Neonatal Abstinence Syndrome Guidelines Reference Number: CP.MP.86 Effective Date: 10/13

Child Welfare and MOMS: Building Partnerships to Improve Care

Opioid Use and Other Trends

ADDRESSING THE OPIOID EPIDEMIC. Joint principles of the following organizations representing front-line physicians

Consequences and Treatment of Opioid Abuse During Pregnancy. Katie Ellis, PharmD March 12, 2018

Substance-Exposed Newborn

Johann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works

Product Labeling to Communicate Benefits and Risks of Treatment for Opioid Use Disorder in Pregnant Women. Hendrée E. Jones, PhD

Opiate Use in Reproductive Age Females

ADDICTION IN PREGNANCY

Presented by DCF SunCoast Region: Kyle Teague, Melissa Worthen, Christina Cuoco, Nina Romeu, Dekesha Seay

EAT, SLEEP, CONSOLE The Yale Method of assessment and treatment of neonates during withdrawal from opiates

A New approach to NAS: home in 6 days

An Adaptive Reinforcement-Based Treatment (RBT) Intervention for Pregnant Substance Dependent Women

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond

ASTHO President s Challenge 15 x 15: Reduce Prescription Drug

Data Integration and Analysis for Improved Drug Overdose Surveillance in Kentucky

Multidisciplinary Management of the Opioid Crisis To Optimize Perinatal Outcome in a Rural Women s Clinic Population

Public Policy Statement on Substance Use, Misuse, and Use Disorders During and Following Pregnancy, with an Emphasis on Opioids

Substance-Exposed Newborns

... Health. Department of. Prenatal Drug Exposure and Neonatal Abstinence Syndrome in Northeast TN. Overview and Regional Snapshot

OPQC Learning Session: High Risk Moms & Infants. Mary Applegate, MD, FACP, FAAP Medical Director, Ohio Department of Medicaid September 2016

PROJECT DOVE. Improving Maternal and Neonatal Health Through Safer Opioid Prescribing MODULE 3

IN-PATIENT PEDIATRIC REHABILITATION

MAT in the Corrections Setting

8/24/2015 ADDICTION AND PREGNANCY. Fear ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY

Anesthetics, Local a / or Anesthesia, Epidural a / or Anesthesia, Obstetrical a / or Pain, Postoperative a / or Postpartum Period a

OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC:

Neonatal Abstinence: It s No Child s Play!

OB Well Baby Nursery Admission (Term) [ ] For specialty focused order sets for your patient, refer to: General

DPH Priorities and Statewide Initiatives

Emergent Issues Affecting Early Intervention/ Early Childhood. Workforce Development for Inclusion in Early Childhood November 4, 2017 Washington, DC

Strategies to Manage The Opioid Crisis

IDENTIFICATION AND MANAGEMENT OF PERINATAL SUBSTANCE ABUSE

2/24/2017. Pregnant Women Who Use Drugs: Stigma, Science and Society

8/27/2018. Katie Brooks, DO, FAAP CHI Health St. Elizabeth. I have nothing to disclose

Medication for the Treatment of Addiction (MAT)

The Opioid Addiction Crisis in the Northern Shenandoah Valley. A Community Response

Opioid Use Disorder. in Pregnancy: Care and Context of Mother and Newborn

Strategies for Federal Agencies

Wales Neonatal Network Guideline

CDC s Efforts to End the Opioid Epidemic

Why NAS? Proposed Program

Continuing Education Webinar The Pregnancy Opioid Epidemic: An Outpatient Medical Home Approach to Treatment

NAS / NOWS: Description. Disclosures: I will discuss off-label uses of medications I have no financial disclosures. Objectives

Indiana CTSI Retreat 2018

Science = Solutions For Substance Use Disorders and Infant Outcomes. Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse

EI Leadership April 24, 2018

Development and use of the Eating, Sleeping, Consoling (ESC) Care. for opioid-exposed newborns and their families in Northern New England

Running head: NEONATAL ABSTINENCE SYNDROME 1

Texas Strategies to Address the Opioid Crisis and Neonatal Abstinence Syndrome

The Substance Exposed Newborn Alphabet Soup

Transcription:

Opioid use in pregnancy and Neonatal Abstinence Syndrome Morissa Ladinsky, MD Assoc. Professor of Pediatrics Division of General Pediatrics and Adolescent Medicine UAB

Objectives 1. Understand the magnitude, medicine and scope of neonatal abstinence syndrome. 2. Obtain insights from Ohio s statewide Neonatal/Perinatal Collaborative work using QI methodology to improve NAS care. 3. Learn concrete, data driven public health measures and best practice approaches to the immense challenge of substance use in pregnancy.

Opioid Epidemic; Pregnant Moms and Babies 2000-2009 2000-2009 4 fold increase in OPR prescriptions. Enough prescription opioids were prescribed in 2010 to medicate every American adult around-the-clock for a month. US infants diagnosed with NAS increased x3 By 2009, 1 infant per hour accounting for $720 million Patrick, SW et al, JAMA, 2012, 307(18), Pediatrics, 2015 135(5)

Ohio Data:

At delivery Abrupt adjustment to Extrauterine life AND A drug-free environment Withdrawal

What is Neonatal Abstinence Syndrome The clinical findings associated with opioid withdrawal has been termed the neonatal abstinence syndrome (NAS). Nearly all exposed infants will display some symptoms, but only a subset require treatment. Opioid receptors concentrated in CNS and GI tract. NAS affects baby s ability to be alert, sleep, eat, communicate cues PEDIATRICS Vol. 129 No. 2 February 1, 2012 135, August 2014. PEDIATRICS Vol.

Clinical Timeline SUBSTANCE ONSET (hours) DURATION (days) Heroin 24-48 8-10 Methadone 48-72 Up to 30+ Buprenorphine 36-60 Up to 28 Prescription opioids 36-72 10-30 Polypharmacy???? Fentanyl????

Discharge at 48 hrs??? AAP (2014 and 2017) WHO (2014) Known fetal exposure: 4-7 days! 1 in 5 has onset after 48 hrs Withdrawal at home Poor feeing Vomiting and diarrhea Extreme irritability Sleep challenges DEHYDRATION SEIZURES RISK FOR CHILD ABUSE Pediatrics 2012, 2014, KY NAS Registry, 2015, Pediatrics 2017

A Big Road Runs Through It

12

13

14

15

Projects: OCHA & OPQC Sept. 2012 Sept. 2014 Six children s hospitals and their affiliates (20 total hospitals) 994 infants Included only infants that required pharmacological treatment for NAS January 2014-June 2016 54 sites: 26 Level II NICU s 26 Level II Special Care Nurseries 2 Normal Newborn Nurseries 6131 infants in the database Includes infants that receive both non-pharmacological AND pharmacological treatment

Improve Consistency in Modified Finnegan Scoring Attain high reliability in NAS scoring by nursing staff Intervention: Fulltime RN staff at Level 2 and 3 hospitals to complete D Apolito NAS scoring training video and achieve 90% reliability. All sites use same tool Train RN staff to 90% reliability in scoring using D Apolito Training System OPQC has sent out DVD s to each site

Pharmacological Bundle Key Driver: Standardize NAS Treatment Protocol Interventi on: Initiate Rx If NAS score > 8 twice. Stabilization/ Escalation Phase Begin wean when stable for 48hrs Discharge home after 48hrs (Morphine) to 72hrs (Methadone)

Impact of Ohio OCHA Weaning Protocol 2012-2014 with 199 centers. N=3458 infants with NAS 50 45 40 35 30 25 20 Opiate Treatment days Day of Life of Discharge 15 10 5 0 N=102 N=183 N=187 N=29 N=32 N=14 N=547 A B C D E F Total

Non-Pharmacological Bundle Key Driver: Optimize Non-Pharmacologic Rx Bundle Intervention Swaddling, low stimulation. Encourage kangaroo care Feed on demand- MBM if appropriate lactose free 22 cal formula

METHODS OF SCREENING/TESTING Maternal Interview Screen Maternal Urine Drug Test Infant Urine Drug Test Meconium Toxicology Test Umbilical Cord Toxicology Test Screen vs. Test

Risk based screen In 2012 Mercy Hospital Anderson cared for: 1,868 neonates born to 1,874 women 96% were Caucasian, 52% were married, and 51% had private insurance

Universal Testing Pilot We evaluated the efficacy of a universal testing protocol for all mothers in a community hospital setting that experienced a three-fold increase in neonatal abstinence syndrome (NAS) Positive Risk Based Screen 77/96 (80%) Positive for Opiates 96/2,956 (3.2%) Negative Risk Based Screen 19/96 (20%) Positive Test Results 159/2,956 (5.4%) Positive for Others 63/2,956 (2.1%) Positive Risk Based Screen 46/63 (73%) Negative Risk Based Screen 17/63 (27%) Number of Negative Risk based screen infants needing additional care for signs and symptoms of NAS 7/19 (37%) Total Number of Positive tests with a Negative Risk Based Screen 36/159 (23%) Wexelblatt S, et al. J Pediatrics, 166, March, 2015

Universal Testing, OH/KY 18 hospitals in our region now doing universal testing (2015) Delivery Service Hospitals Atrium Medical Center The Christ Hospital Dearborn County Hospital Kettering Health Network Highland District Hospital Margaret Mary Hospital Mercy Health Partners St Elizabeth Hospital TriHeatlh UC Health Being able to start nonpharmacological bundle earlier, may lead to a decrease in percentage of infants requiring medications for NAS.

Perinatal Institute Neonatal Abstinence Syndrome Management Process Map This is a suggested guideline, each hospital may have unique circumstances which requires a different process than suggested Admission to Labor and Delivery Consent for universal maternal testing? Y Send maternal toxicology test Is maternal toxicology test positive? Y 1.Send newborn 1 st urine (initiate process in delivery room) 2.Send cord or meconium 3.Social Work consult N Missed first maternal test Is there a history of illicit drug/opiate use during pregnancy? Y N N Routine care Send newborn 1 st urine and/or send umbilical cord Is drug test + for buprenorphine/ methadone? N Is drug test + for other opioid? N Is drug test + for other drugs? Y Y Y Observe for 96 hrs, initiate Finnegans 6-24 hrs after birth and begin non pharmacological interventions Observe for 72 hrs, initiate Finnegans 6-24 hrs after birth and begin non pharmacological interventions No Finnegan s, apply code: Cocaine 760.75 THC 760.73 Routine care Are Finnegan scores 8x3 or 12x2? N Apply code-760.72, call PCP prior to discharge Y Begin pharmacologic treatment protocol, apply NAS code (779.5) Schedule clinic appt, call PCP prior to discharge

Cincinnati Region: Drug Exposure Rate per 1,000 births (8.5 fold increase) Data from delivery hospitals ICD9/ICD10 codes 100 90 Any drug exposure per 1,000 births Cincinnati Region 88.3 80 70 60 50 53.2 69.0 63.3 40 34.5 30 24.5 20 10 10.4 15.8 0 2009 2010 2011 2012 2013 2014 2015 2016

Days LOS and DOT for NAS infants CCHMC Perinatal Institute 25 22.1 Pharmacologic Treated Infants 21 20 15 10 17.1 15.5 18.4 13.2 16.5 11.5 5 0 2013 2014 2015 2016*. DOT LOS

Breastfeeding and Substance Use

Breastfeeding and Substance Use AAP committee recommends all mothers in methadone/buprenorphine treatment be allowed to breast-feed regardless of dose. Data suggests a protective effect on the rate of NAS. (May be non-pharm bundle effect) HCV and HBV not contraindication for breast feeding HIV contraindications in developed countries AAP: Committee on Drug. Pediatrics 2001 and 2013

Breastfeeding and maternal substance use--perinatal Institute No HM Poly drugs Mother or infant with a positive toxicology Y THC only Educate and encourage to stop usage. OK to feed HM Opioids only N OK to feed HM Mom in treatment program? Y OK to feed HM N Consult with Attending Verify dose with prescribing physician Y Prescribed opioids for pain? N No HM

Criminal Justice Approaches to Substance Use in Pregnancy Prosecution and punishment of pregnant women who use illicit substances, have no proven benefits for infant health. Formally affirmed by: American Academy of Pediatrics American Association of Family Practice American College of OB/GYN American Nurses Association American Medical Association American Psychiatric Association National Perinatal Association American Society of Addiction Medicine March of Dimes American Public Health Organization Patrick, SW and AAP Committee on Substance Use and Prevention, Pediatrics, 139(3), 2017.

Chemical endangerment Ohio parents arrested after 8-year-old son overdosed on heroin, police say By Amy B Wang February 20 Ohio parents arrested after 8-year-old found with heroin in system https://t.co/e4sxv4ewxe pic.twitter.com/6qsp8scm2x WPXI (@WPXI) February 18, 2017

Chemical Embarrassment

Pediatrics, 2017;139(3) Primary Prevention Improved Identification and Access to Treatment Criminal Justice Approach

Primary Prevention 1) Provider education re: abuse 2) Bolstering PDMP s 3) Proper disposal 4) Empower law enforcement around illegal prescribing. Unintended pregnancy : 31-45% vs 85-90% in SUD women LARC!!!!!

Identification/Treatment/Criminal Justice Opioid agonist therapy Medication assisted treatment Coordinated effort with transparency and communication Funding for EI, DHR